UBS Asset Management Americas Inc. Grows Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

UBS Asset Management Americas Inc. raised its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 6.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 43,811 shares of the company’s stock after purchasing an additional 2,724 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in Amphastar Pharmaceuticals were worth $883,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Captrust Financial Advisors increased its position in shares of Amphastar Pharmaceuticals by 1,889.3% during the first quarter. Captrust Financial Advisors now owns 1,492 shares of the company’s stock worth $27,000 after acquiring an additional 1,417 shares during the last quarter. FORA Capital LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth about $27,000. Lazard Asset Management LLC purchased a new stake in shares of Amphastar Pharmaceuticals during the second quarter worth about $70,000. Royal Bank of Canada increased its position in shares of Amphastar Pharmaceuticals by 253.4% during the second quarter. Royal Bank of Canada now owns 3,534 shares of the company’s stock worth $71,000 after acquiring an additional 2,534 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky increased its position in shares of Amphastar Pharmaceuticals by 46.9% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 10,331 shares of the company’s stock worth $189,000 after acquiring an additional 3,300 shares during the last quarter. 56.49% of the stock is currently owned by institutional investors.

A number of analysts have recently issued reports on AMPH shares. Zacks Investment Research raised Amphastar Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $24.00 target price on the stock in a research report on Monday, November 15th. TheStreet upgraded Amphastar Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Wednesday, October 20th.

NASDAQ:AMPH opened at $20.92 on Thursday. The firm has a market capitalization of $1.00 billion, a P/E ratio of 29.06 and a beta of 0.70. Amphastar Pharmaceuticals, Inc. has a one year low of $16.91 and a one year high of $21.70. The stock has a 50-day moving average price of $19.42. The company has a quick ratio of 2.08, a current ratio of 3.10 and a debt-to-equity ratio of 0.18.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Monday, November 8th. The company reported $0.46 EPS for the quarter, topping the Zacks’ consensus estimate of $0.24 by $0.22. Amphastar Pharmaceuticals had a return on equity of 12.28% and a net margin of 8.74%. During the same period in the prior year, the business earned $0.09 earnings per share. As a group, analysts expect that Amphastar Pharmaceuticals, Inc. will post 1.11 earnings per share for the current fiscal year.

In other Amphastar Pharmaceuticals news, Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Monday, November 22nd. The stock was sold at an average price of $21.22, for a total value of $106,100.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rong Zhou sold 7,813 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Thursday, November 11th. The shares were sold at an average price of $21.67, for a total value of $169,307.71. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 22,813 shares of company stock valued at $488,708. 28.40% of the stock is currently owned by insiders.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs.

Featured Story: The Role of a Fiduciary and Individual Investors

Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).

Institutional Ownership by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.